MedTrace Logo

Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study

NCT05977881 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 493

Last updated 2026-05-14

No results posted yet for this study

Summary

Through the proposed Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement (SCOPE) study, the investigators will design and evaluate an overdose prevention and HIV prevention study among people who use drugs (PWUD). Specifically, SCOPE will provide access to drug-checking services for PWUD to better understand the contents of the drug supply, in combination with PrEP for those who are HIV-, to both reduce overdose and HIV among PWUD in Baltimore City.

Conditions

  • HIV Infections

Interventions

OTHER

CHECKIT!

Participants will not be assigned to the intervention as it will be available to everyone. Check it will be a van-based HIV- and overdose-prevention program offered in the four areas of Baltimore city from which study participants are recruited. Intervention services will include point-of-care drug checking and PrEP assessment, prescription, and management, and they will be available to everyone, regardless of whether they are part of the SCOPE study cohort or not. Individual-level service usage data collected by intervention staff will not be considered in analysis of outcomes. However, study participants will self-report Check it utilization on the internally-developed surveys at 6, 12, and 18 months.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Baltimore City Health Department

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Principal Investigators

  • Susan Sherman, PhD · Johns Hopkins Bloomberg School of Public Health

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-28
Primary Completion
2026-05-01
Completion
2026-05-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05977881 on ClinicalTrials.gov